Physician profile
Vincent E Salerno
NPI 1881634202
$7,892.16
in general payments reported to CMS, 2019-2025
50 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $426 · 2021: $257 · 2022: $818 · 2023: $2,299 · 2024: $1,904 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,964 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,963.72 |
| Education | $182.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,196.33 | 2022-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $550.19 | 2020-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $511.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $455.16 | 2019-2025 | Injectafer, Vanflyta, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $407.90 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $397.36 | 2020-2025 | Lynparza, Enhertu |
| Gilead Sciences, INC. | $370.93 | 2022-2025 | Trodelvy |
| Seagen INC. | $267.07 | 2021-2023 | Tukysa, Padcev |
| Celgene Corporation | $259.11 | 2020-2025 | Reblozyl |
| Pfizer INC. | $244.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $230.57 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $222.87 | 2019-2025 | |
| Taiho Oncology, INC. | $221.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $209.48 | 2022-2025 | |
| Lilly USA, LLC | $198.54 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $181.43 | 2020-2025 | |
| Incyte Corporation | $151.96 | 2019-2025 | Jakafi |
| Amgen INC. | $147.94 | 2022-2023 | Lumakras, Kyprolis |
| Janssen Biotech, INC. | $141.21 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $131.94 | 2022-2025 | Xtandi |
| Glaxosmithkline, LLC. | $125.15 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $122.40 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Aveo Pharmaceuticals, INC. | $112.48 | 2024 | |
| Dendreon Pharmaceuticals LLC | $90.57 | 2023-2024 | Provenge |
| Abbvie INC. | $89.23 | 2024-2025 | |
| Novocure INC. | $80.83 | 2020-2025 | Optune, Optune Lua (Novottf-200t) |
| Takeda Pharmaceuticals U.S.A., INC. | $76.89 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Array Biopharma INC | $76.09 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Legend Biotech USA INC. | $63.37 | 2024-2025 | Carvykti |
| Pharmaessentia USA Corporation | $57.91 | 2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $55.39 | 2023-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $46.81 | 2023-2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $44.08 | 2020-2021 | |
| Foundation Medicine, INC. | $41.21 | 2023 | |
| Kite Pharma, INC. | $34.18 | 2020-2022 | |
| Emd Serono, INC. | $32.34 | 2024-2025 | |
| Genmab U.S., INC. | $32.23 | 2022-2023 | Tivdak |
| Stemline Therapeutics INC. | $30.84 | 2025 | Orserdu |
| Macrogenics, INC. | $22.02 | 2022 | |
| Janssen Scientific Affairs, LLC | $19.93 | 2019 | |
| Geron Corporation | $18.49 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $18.30 | 2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $17.40 | 2024 | Empaveli |
| Jazz Pharmaceuticals INC. | $16.94 | 2025 | |
| Telix Pharmaceuticals | $15.60 | 2024 | Illuccix |
| Servier Pharmaceuticals LLC | $15.22 | 2024 | |
| Global Blood Therapeutics, INC. | $15.00 | 2022 | |
| Recordati_rare_diseases_inc. | $12.78 | 2023 | Sylvant |
| Octapharma USA, INC. | $11.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Salerno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.